Rebecca S Heist

Rebecca S Heist

UNVERIFIED PROFILE

Are you Rebecca S Heist?   Register this Author

Register author
Rebecca S Heist

Rebecca S Heist

Publications by authors named "Rebecca S Heist"

Are you Rebecca S Heist?   Register this Author

81Publications

3073Reads

23Profile Views

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.

Cancers (Basel) 2019 Dec 17;11(12). Epub 2019 Dec 17.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11122033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966679PMC
December 2019

Clinical Validation of a Cell-Free DNA Gene Panel.

J Mol Diagn 2019 Jul 23;21(4):632-645. Epub 2019 Apr 23.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2019.02.008DOI Listing
July 2019

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 11 4;36(33):3298-3306. Epub 2018 Oct 4.

John H. Strickler, Duke University Medical Center, Durham, NC; Colin D. Weekes, University of Colorado, Aurora, CO; John Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Ramesh K. Ramanathan, Virginia Piper Cancer Center at Honor Health/Translational Genomics Research Institute, Scottsdale, AZ; Rebecca S. Heist, Massachusetts General Hospital Cancer Center, Boston, MA; Daniel Morgensztern, Washington University School of Medicine, St. Louis, MO; Eric Angevin, Gustave Roussy, Villejuif, France; Todd M. Bauer, Sarah Cannon Research Institute; Todd M. Bauer, Tennessee Oncology, Nashville, TN; Huibin Yue, Daniel Afar, and Louie Naumovski, AbbVie Inc.; Apurvasena Parikh, Clinical Pharmacology and Pharmacometrics, AbbVie Inc., Redwood City; Karen Kelly, University of California Davis Comprehensive Cancer Center, Sacramento, CA; and Monica Motwani, Edward B. Reilly, AbbVie Inc., North Chicago, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.7697
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.7697DOI Listing
November 2018

First-Line Systemic Therapy for Non-Small Cell Lung Cancer.

Authors:
Rebecca S Heist

Hematol Oncol Clin North Am 2017 02;31(1):59-70

Department of Thoracic Oncology, Massachusetts General Hospital, 32 Fruit Street, Yawkey 7B, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2016.08.001DOI Listing
February 2017

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

J Palliat Med 2016 12 14;19(12):1316-1319. Epub 2016 Sep 14.

2 Massachusetts General Hospital Cancer Center , Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jpm.2016.0180DOI Listing
December 2016

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.

J Thorac Oncol 2016 11 20;11(11):2022-2026. Epub 2016 Aug 20.

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864163084
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2016.06.032DOI Listing
November 2016

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

J Thorac Oncol 2016 08 22;11(8):1242-1245. Epub 2016 Jun 22.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.013DOI Listing
August 2016

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

JAMA Oncol 2016 Apr;2(4):541-3

Massachusetts General Hospital Cancer Center, Boston2Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.5009DOI Listing
April 2016

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.

J Thorac Oncol 2015 Aug;10(8):1156-62

*Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; †Department of Pathology, Yonsei University College of Medicine, Seoul, Korea; and ‡Department of Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000579DOI Listing
August 2015

Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer.

Methods 2015 Jul 23;83:118-27. Epub 2015 Apr 23.

Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, United States; Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37232, United States; Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymeth.2015.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509831PMC
July 2015

Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.

Proc Natl Acad Sci U S A 2015 Jul 16;112(27):E3454. Epub 2015 Jun 16.

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1507225112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500270PMC
July 2015

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Jun 20;33(18):2004-12. Epub 2015 Apr 20.

Scott N. Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT; Leora Horn, David P. Carbone, and Jeffrey A. Sosman, Vanderbilt University Medical Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Leena Gandhi, David M. Jackman, and F. Stephen Hodi, Dana-Farber Cancer Institute; Rebecca S. Heist and Lecia V. Sequist, Massachusetts General Hospital Cancer Center; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Scott J. Antonia and Mary C. Pinder-Schenck, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Naiyer A. Rizvi, Richard D. Carvajal, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH; Suzanne L. Topalian, Drew M. Pardoll, and Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; and Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Georgia D. Kollia, and Ashok K. Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3708
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672027PMC
June 2015

Rociletinib in EGFR-mutated non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1700-9

From Massachusetts General Hospital (L.V.S., R.S.H., J.L., Z.P.), Harvard Medical School (L.V.S., G.R.O., R.S.H., Z.P.), and Dana-Farber Cancer Institute (G.R.O.) - all in Boston; the Drug Development Department, Université Paris-Sud, Gustave Roussy Cancer Campus (J.-C.S.), and Institut Gustave Roussy (A.V.), Villejuif - both in France; the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (J.W.G., E.B.G., M.A.M., S.N.), and Stanford Cancer Institute, Stanford University, Stanford (H.A.W., J.W.N.) - both in California; the Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit (S.M.G., C.G., A.J.W.); University of Texas M.D. Anderson Cancer Center, Houston (V.P.); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); the Medical University of Gdansk, Gdansk, Poland (R.D.); the University of Colorado (D.L.A., D.R.C.) and University of Colorado Cancer Center (R.C.D.) - both in Aurora; and Clovis Oncology, San Francisco (M.R., C.A.K., S.J.-T., S.L.M., A.R.A.), Boulder, CO (J.I., D.D.), and Cambridge, United Kingdom (L.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1413654DOI Listing
April 2015

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-63

*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346098PMC
January 2015

Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer.

Cancer Epidemiol Biomarkers Prev 2014 Nov 7;23(11):2503-11. Epub 2014 Aug 7.

Nanjing Medical University, Nanjing, China. Massachusetts General Hospital, Boston, Massachusetts. Harvard School of Public Health, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-14-0389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221531PMC
November 2014

Genotyping lung cancer is an investment in the future.

J Clin Oncol 2014 Nov 8;32(31):3576-7. Epub 2014 Sep 8.

Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.6430DOI Listing
November 2014

The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.

J Thorac Oncol 2014 Sep;9(9):1363-9

*Division of Hematology/Oncology, Department of Medicine; †Division of Thoracic Surgery; ‡Biostatistics Center; §Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston,Massachusetts; and ‖Department of Thoracic Surgery, Guangdong General Hospital, Southern Medical University, Guangdong, China.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153068
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000266DOI Listing
September 2014

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Cancer Res 2014 Jun 27;74(11):3146-56. Epub 2014 Mar 27.

Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046322PMC
June 2014

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Feb;9(2):214-21

*Department of Thoracic Oncology, Massachusetts General Hospital, Boston, Massachusetts; †Department of Oncology, Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina; ‡Department of Oncology, Ohio State University Medical Center, Columbus, Ohio; §Department of Oncology, University of North Carolina, Chapel Hill, North Carolina; ‖Department of Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ¶Department of Oncology, Kinston Medical Specialists, P.A., Kinston, North Carolina; #Department of Oncology, University of Chicago, Chicago, Illinois; and **Department of Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284815PMC
February 2014

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a47162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801424PMC
November 2013

Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.

J Gastroenterol Hepatol 2013 Sep;28(9):1482-8

Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.12286DOI Listing
September 2013

Multidisciplinary management of small cell lung cancer.

Surg Oncol Clin N Am 2013 Apr 9;22(2):329-43. Epub 2013 Jan 9.

Department of Hematology/Oncology, Yale Cancer Center, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2012.12.002DOI Listing
April 2013

Genetic changes in squamous cell lung cancer: a review.

J Thorac Oncol 2012 May;7(5):924-33

Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31824cc334DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404741PMC
May 2012

Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care.

J Clin Oncol 2012 Apr 19;30(12):1310-5. Epub 2012 Mar 19.

Massachusetts General Hospital Cancer Center, Center for Psychiatric Oncology and Behavioral Sciences, Yawkey 9A, 55 Fruit St, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.3166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341144PMC
April 2012

SnapShot: non-small cell lung cancer.

Cancer Cell 2012 Mar;21(3):448.e2

Massachusetts General Hospital, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2012.03.007DOI Listing
March 2012

Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.

Carcinogenesis 2011 Apr 6;32(4):502-6. Epub 2011 Jan 6.

Environmental and Occupational Medicine and Epidemiology Program, Department of Environmental Health, Harvard School of Public Health, and Department of Medicine, Massachusetts General Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/carcin/article-lookup/doi/10.1093/c
Publisher Site
http://dx.doi.org/10.1093/carcin/bgq287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066416PMC
April 2011

Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma.

Neoplasia 2011 Apr;13(4):386-92

Environmental and Occupational Medicine and Epidemiology Program, Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071087PMC
http://dx.doi.org/10.1593/neo.101722DOI Listing
April 2011

A Large-scale genetic association study of esophageal adenocarcinoma risk.

Carcinogenesis 2010 Jul 7;31(7):1259-63. Epub 2010 May 7.

Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgq092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893800PMC
July 2010

Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.

J Thorac Oncol 2009 Sep;4(9):1170-3

Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155608641531558
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e3181b28efeDOI Listing
September 2009

Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.

Clin Cancer Res 2009 Jul 7;15(14):4680-5. Epub 2009 Jul 7.

Medical Oncology and Haematology, Department of Medicine, Princess Margaret Hospital, Ontario Cancer Institute, University of Toronto,Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742698PMC
July 2009

Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.

Carcinogenesis 2009 May 25;30(5):793-8. Epub 2009 Mar 25.

Medical Oncology and Hematology, Biostatistics, Princess Margaret Hospital and Department of Medicine, Dalla Lama School of Public Health and University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgp065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675656PMC
May 2009

Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.

Cancer Causes Control 2008 Dec 14;19(10):1077-83. Epub 2008 May 14.

Department of Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-008-9171-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106102PMC
December 2008

MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.

Clin Cancer Res 2008 Jun;14(12):4010-5

Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4187DOI Listing
June 2008

Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.

Int J Cancer 2008 Feb;122(4):915-8

Applied Molecular Oncology/Department of Medicine, Ontario Cancer Institute/Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.23178DOI Listing
February 2008

Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?

Nat Clin Pract Oncol 2007 Oct 31;4(10):564-5. Epub 2007 Jul 31.

Medical Oncologist at the Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc0909DOI Listing
October 2007

Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients.

Clin Cancer Res 2006 Dec;12(23):7187-93

Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1460DOI Listing
December 2006

Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients.

Cancer Epidemiol Biomarkers Prev 2006 Nov;15(11):2239-45

Departments of Environmental Health, Occupational Health Program, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-06-0023DOI Listing
November 2006